Skip to main content

Advertisement

SpringerLink
Log in

Effect of hydromorphone on ventilation in palliative care patients with dyspnea

  • Short Communication
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Goals

This study assessed the effect of hydromorphone treatment on ventilation and the intensity of dyspnea in palliative care patients. The assessments measured changes in peripheral oxygen saturation (SaO2), transcutaneous arterial pressure of carbon dioxide (tcpaCO2), respiratory rate (f), and pulse frequency (PF) during the titration phase with hydromorphone for symptomatic therapy of dyspnea. The aims of the study were to verify the efficacy of hydromorphone for the management of dyspnea and assess its effect on ventilation.

Materials and methods

Fourteen patients admitted to our palliative care unit were included in this prospective, nonrandomized trial. At admission, all patients suffered from dyspnea. TcpaCO2, SaO2, and PF were measured transcutaneously by means of a SenTec Digital Monitor (SenTec AG, Switzerland).

Main results

As early as 30 min after the first hydromorphone application, mean respiratory rate decreased from 38.8 ± 4.9 breaths/min (range 30.0–45.0 breaths/min) to 34.6 ± 4.2 breaths/min (29.0–41.0 breaths/min); after 120 min to 29.0 ± 3.1 breaths/min (range 24.0–33.0 breaths/min) (p = 0.001). The other monitored respiratory parameter, however, showed no significant changes. A significant improvement was shown in the intensity of dyspnea [numeric rating scale 0–10: 5.2 ± 1.5 (4–8)/6.4 ± 2.1 (4–10) vs 1.1 ± 0.9 (0–3)/2.3 ± 1.3 (1–5); p = 0.001].

Conclusions

Neither was there a significant decrease in SaO2 nor a significant increase in tcpaCO2 after the initial hydromorphone application, i.e., there was no hydromorphone-induced respiratory depression. The first hydromorphone application, however, resulted in a significant decrease in the intensity of dyspnea and respiratory rate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Abernethy AP, Currow DC, Frith P et al (2003). Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 327:523–528

    Article  PubMed  CAS  Google Scholar 

  2. Babul N, Darke AC, Hagen N (1995) Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage 10(3):184–186

    Article  PubMed  CAS  Google Scholar 

  3. Bennetton SA, Borges VM, Chang TKH, McErlane KM (2004) Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone. Xenoptica 34(4):3335–3344

    Google Scholar 

  4. Berkenbosch A, Olivier CN, Wosink JG, deGoede J, Ruprecht J (1994) Effect of morphine and physiostigmine on the ventilatory response to carbon dioxide. Anesthesiology 80:1303–1310

    Article  PubMed  CAS  Google Scholar 

  5. Berkenbosch A, Teppema LJ, Olivier CN, Dahanan A (1997) Influences of morphine on the ventilatory response to isocapnic hypoxia. Anesthesiology 86:1342–1349

    Article  PubMed  CAS  Google Scholar 

  6. Bourke DL, Warley A (1989) The steady state and breathing methods compared during morphine administration in humans. J Physiol 419:509–517

    PubMed  CAS  Google Scholar 

  7. Bruera E, MacEachern T, Ripamonti C, Hanson J (1993) Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med 119:906–907

    PubMed  CAS  Google Scholar 

  8. Bruera E, Macmillan K, Pither J et al (1990) Effects of morphine on the dyspnoea of terminal cancer patients. J Pain Symptom Manage 5:341–344

    Article  PubMed  CAS  Google Scholar 

  9. Bruera E, Sweeny C, Ripamonti C (2002) Management of dyspnea. In: Berger A, Portenoy R, Weissman D (eds) Principles and practice of palliative care and supportive oncology. Williams & Wilkins, Philadelphia, pp 357–371

    Google Scholar 

  10. Clemens KE, Klaschik E (2007) Symptomatic therapy of dyspnoea with strong opioids and its effect on ventilation in palliative care patients. J Pain Symptom Manage 33(4):473–481

    Article  PubMed  CAS  Google Scholar 

  11. Clemens KE, Klaschik E (2007). Respiratorische Symptome. In: Aulbert E, Nauck F, Radbruch L (eds) Lehrbuch der Palliativmedizin. 2. Auflage. Schattauer, Stuttgart, pp 375–393

    Google Scholar 

  12. Cone EJ, Darwin WD (1978) Simultaneous determination of hydromorphone, hydrocodone and their 6α and 6β hydroxyl metabolites in urine using selected ios recording with methane chemical ionization. Biomed Mass Spectrum 5:291–295

    Article  CAS  Google Scholar 

  13. Evans KC, Banzett RB, Adams L, McKay L, Frackowiak RSJ, Corfield DR (2002) BOLD fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger. J Neurophysiol 88:1500–1511

    PubMed  Google Scholar 

  14. Farncombe M, Chater S (1994) Clinical application of nebulised opioids for treatment of dyspnoea in patients with malignant disease. Support Care Cancer 2:184–187

    Article  PubMed  CAS  Google Scholar 

  15. Farncombe M, Chater S, Gillin A (1994) The use of nebulised opioids for breathlessness: a chart review. Palliat Med 8:306–312

    Article  PubMed  CAS  Google Scholar 

  16. Gross JB, Blouin RT, Zandsberg S, Conrad PF, Häusler J (1996) Effect of flumazenil on ventilatory drive during sedation with midazolam and alfentanyl. Anesthesiology 85:713–720

    Article  PubMed  CAS  Google Scholar 

  17. Hagen NA, Foley KM, Cerbone DJ et al (1991) Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manage 6(3):125–128

    Article  PubMed  CAS  Google Scholar 

  18. Heyse-Moore LH, Ross V, Mullee MA (1991) How much of a problem is dyspnoea in advanced cancer? Palliat Med 5:20–26

    Article  Google Scholar 

  19. Klaschik E (2006) Dyspnoe. In: Husebø S, Klaschik E (eds) Palliativmedizin. Aktualisierte, 4. Auflage. Springer, Berlin, Heidelberg, New York, pp 276–279

    Google Scholar 

  20. Lawlor P, Turner K, Hanson J, Bruera E (1997) Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain 72:79–85

    Article  PubMed  CAS  Google Scholar 

  21. Mazzocato C, Buclin T, Rapin C (1999) The effects of morphine on dyspnoea and ventilatory function in elderly patients with advanced cancer: a randomized double blind controlled trial. Ann Oncol 10:1511–1514

    Article  PubMed  CAS  Google Scholar 

  22. Moriarty M, McDonald CJ, Miller A (1999). A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. J Clin Res 2:1–8

    Google Scholar 

  23. Quigley C (2002) Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev (1):CD003447

  24. Santiago TV, Johnson J, Riley DJ Edelman NH (1979) Effects of morphine on ventilatory response to exercise. J Appl Physiol 47:112–118

    PubMed  CAS  Google Scholar 

  25. Sarhill N, Walsh D, Khawam E, Tropiano P, Stahley MK (2000) Nebulized hydromorphone for dyspnoea in hospice care of advanced cancer. Am J Hosp Palliat Care 17(6):389–391

    Article  PubMed  CAS  Google Scholar 

  26. Weil JV, McCullough RE, Kline JS, Sodal I (1975) Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal men. N Engl J Med 292:1103–1106

    Article  PubMed  CAS  Google Scholar 

  27. Wilson RH, Hoshet W, Dempsey ME (1954) Respiratory acidosis: effects of decreasing respiratory minute volume in patients with chronic pulmonary emphysema, with specific reference to oxygen, morphine and barbiturates. Am J Med 18:464–470

    Article  Google Scholar 

  28. Zebraski SE, Kochenash SM, Raffa RB (2000) Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci 66:2221–2231

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Birgit Jaspers for careful review of this manuscript and English editing. This study is sponsored by Deutsche Krebshilfe e.V. (German Cancer Aid). The sponsor had no impact on the investigator-initiated work of the authors.

Author information

Authors and Affiliations

  1. Department of Anaesthesiology, Intensive Care Medicine, Palliative Medicine and Pain Therapy, Malteser Hospital Bonn/Rhein-Sieg, Von-Hompesch-Strasse 1, 53123, Bonn, Germany

    Katri Elina Clemens & Eberhard Klaschik

  2. Centre for Palliative Medicine, Department of Science and Research in Palliative Medicine, Friedrich-Wilhelms-University of Bonn, Bonn, Germany

    Katri Elina Clemens & Eberhard Klaschik

Authors
  1. Katri Elina Clemens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eberhard Klaschik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katri Elina Clemens.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clemens, K.E., Klaschik, E. Effect of hydromorphone on ventilation in palliative care patients with dyspnea. Support Care Cancer 16, 93–99 (2008). https://doi.org/10.1007/s00520-007-0310-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-007-0310-3

Keywords

Search

Navigation